posit
month-to-d head earn biotech indic
absolut rel basi btk nbi vs mid-cap
coverag fare better coverag stock biotech
month-to-d largest clovi least
expect see top-lin beat
maintain estim rate price target
expect tibsovo revenu line consensu pg
achiev focu upcom top-line readout phase breast
remain rubraca sale growth progress toward expand beyond
expect firdaps revenu substanti better pg
revenu line-to-abov consensu pg
jakafi sale line consensu pg
expect giapreza revenu slightli consensu pg
gene therapi readout pg
tabl content
comp sheet strh biotechnolog coverag univers
page
comp sheet strh biotechnolog coverag univers
suntrust robinson humphrey research factset price intra-day juli
page
agio pharmaceut expect tibsovo revenu line consensu focu
call around usag dynam tibsovo pipelin progress
summari expect tibsovo revenu line consensu mn vs consensu
mn expect focu earn call updat on-going
commerci launch wholly-own tibsovo yr post-approv r/r aml month aml
pipelin progress upcom data catalyst earlier pipelin candid
compani report factset strh research estim juli
report date earn call thursday august et us dial-in code
focu remain on-going tibsovo launch would surpris see sale
approxim line consensu street mn look trend underli volum
growth color recent aml approv follow miss trim estim
mn mn see note would surpris see tibsovo
sale line consensu trim near-term estim continu
posit underli demand unit volum growth watch updat trend underli
demand growth uptak commun set clinic day kol note
venetoclax becom go-to drug see note use free drug
remain posit use combin r/r set aml see clear place
tibsovo also look color recent approv tibsovo aml approv may
focu pipelin progressmtap-delet tumor inhibitor readout
proof-of-concept data thalassemia pkr activ mitapivat expect manag
reiter focu guidanc data inhibitor mtap-delet solid tumor
like medic meet fall deeper pipelin proof-of-concept data
pyruv kinase-r pkr activ mitapivat beta-thalassemia program expect
data dose-escal phase expect toler safeti profil biomark data
methionin look earli anti-tumor activ solid tumor basket interest lung
pancreat pkd program expect proof-of-concept data beta-thalassemia expect
g/dl treat patient
potenti posit catalyst sept oct esmo full data claridhi phase studi
tibsovo cholangiocarcinoma phase dose escal data mtap delet
tumor proof-of-concept data beta-thalassemia pkr activ mitapivat
page
metric mn except epsstrh metric tibsovo sale pipelin tibsovo expect sale line non-ev
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt idhifa
r/r aml tibsovo r/r aml solid tumor
mitapivat pk defici cash/pipelin bull/bear case model yield
pt risk relat disappoint clinic data regulatori partnership commerci
risk competit aml space
page
page
assettimingcatalystcommentaryimpacttrialtargettibsovo ivosidenib sept oct esmo data phase claridhi studi cholangiocarcinoma expect mpf snda approv set enrol tibsovo vidaza phase agil enrol registr enabl phase trial dose escal data mtap-delet tumor believ favor side effect profil dlt earli sign anti-tumor phase dose escal trial dhodh depend hematolog malign dhodhmitavipat proof-of-concept data -thalassemia expect see hb level increas enrol random pivot activ trial pk enrol singl arm pivot activate-t trial pk data pivot studi adult polycyst kidney diseas biotechnolog
page
consensu look achiev focu upcom top-line readout phase
summari expect full year guidanc reiter street consensu mn look achiev
focu full year revenu importantli upcom top-line readout phase oral chemotherapi
agent oraxol breast cancer expect top-line data oraxol metastat breast cancer mid-august
possibl market next year see preview
compani report factset strh research estim juli
report date unconfirm potenti third week august base time last year updat
revenu estim look achiev focu fy estimates/guid
importantli potenti top-line phase august revenu consensu adjust
follow revenu beat mn mn street better align guidanc
estim held steadi go quarter expect reiter product sale
mnwhich equat guidanc mn
mn midpoint mn
look top-line phase readout oral chemotherapi paclitaxel oraxol metastat breast
cancer mid-augustw believ posit data like expect top-line data athenex
phase trial oraxol metastat breast cancer august howev note manag tend
beat timelin manag mention hope data earn
usual host mid-august believ improv safeti iv paclitaxel key believ
posit top-line readout p-valu like expect orr oraxol well
orr superior iv paclitaxel patient possibl drive stock
neg data potenti push stock view manag
guid full present later appropri medic confer public follow
top-line data expect nda submiss month remain posit
outlook oraxol breast cancer believ phase success drive greater comfort around
expect progress made toward possibl launch oraxol follow recap quarter
clinic updat see note clinic updat
kinas inhibitor tirbanibulin expect commerci updat discuss progress
toward possibl launch oraxol believ product sale compound
busi help commerci launch oraxol oncolog drug pipelin
expect updat progress made rais brand awar athenex oncolog
develop relationship within oncolog commun follow recent temporari
voluntarili shutdown activ pharmaceut ingredi api plant chongq china see note
expect updat plant complet new york eastern
chongq china believ complet plant help becom independ
page
metric mn except epsstrh metric data readout oraxol non-ev
manufactur api believ oraxol metastat breast cancer market next
potenti posit catalyst august phase top-line data oraxol
metastat breast cancer initi phase data oraxol pembrolizumab multipl solid
tumor earli updat phase data oraxol cutan angiosarcoma
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt oraxol
breast cancer oraxol gastric cancer kinas glioblastoma actin
keratosi tcr-t ny-eso basket cash/pipelin bull/bear case model
yield pt risk relat disappoint clinic data intellectu properti
regulatori competit solid cancer space
page
page
assettimingcatalystcommentaryimpacttargetpartneroraxolaug top-line data metastat breast cancer expect better safeti iv nda metastat breast phase data cutan angiosarcoma expect high cr rate phase bladder gastric nsclc cancer expect see earli respondersmediummayo kinas phase china glioblastoma studi use new formul expect enhanc efficaci kinas tubulin polymerizationposs phase data china phase solid phase solid ind multipl tcr-t ind us phase solid tumor posit possibl phase data china solid tumor nda meet actin keratosi earli nda actin keratosi biotechnolog
page
quarterli breast cancer- oraxol gastric cancer- kinas actin keratosis- kinas glioblastoma- total product revenues- royalti fee consult revenu mileston grant collab incom incom incom ep share outstand biotechnolog
clovi oncolog focu remain rubraca sale growth progress toward expand
summari expect rubraca sale line consensu mn revenu growth
focus second-lin ovarian mainten set expect earn focu market dynam
revenu growth updat on-go eu launch reiter plan expand beyond
ovarian parp inhibit vegfr inhibitor lucitanib expect updat prostat data rucaparib
late sept esmo sept oct file snda
compani report factset strh research estim juli
report date earn call thursday august et us dial-in code
expect rubraca sale line consensu expect rubraca revenu line
consensu approxim line street mn vs mn repres
q/q growth expect free drug remain around report expect rubraca
market share ovarian parp market least look updat eu launch
rubraca sale help launch germani
consensu rucaparib mn hold steadi head quarter revenu
rel tight cluster mn mn analyst upward revis
estim mn follow beat exhibit estim remain rel static
head quarter come approxim mn month
red miss earn non-gaap revenu sale plu royalti exclud mileston green beat grey
in-line price reaction reflect stock reaction day prior earn compar day earn
focu expans indicationsupd prostat data late sept main focu
stock remain expans indic clovi expect present updat interim data
phase rubraca monotherapi prostat cancer late sept esmo sept oct
submit snda rubraca brca-mut advanc metastat castration-resist prostat
cancer mcrpc remind last data updat esmo show
confirm orr see note believ clovi data prostat cancer
look well posit versu jnj/gsk data see note februari
also look updat progress vegfr inhibitor lucitanib
page
metric mn except epsstrh metric rubraca rubraca expect line reaction biotechnolog
on-going trial rucaparib parp
phase studi current evalu rucaparib chemo relaps brca-mut
phase athena studi current evalu rucaparib combin opdivo
mainten treatment follow treatment ovarian patient
phase ari trial current evalu rucaparib combin opdivo ovarian
bladder
phase current evalu rucaparib metastat castration-resist prostat
cancer mcrpc associ homolog recombin defici
phase current evalu rucaparib metastat castration-resist prostat
cancer mcrpc associ homolog recombin defici enrol remind
last saw encourag orr confirm respons
see note
manag expect snda rucaparib later line mcrpc
phase ruca-j current evalu rucaparib japanes patient solid tumor
on-going trial lucitanib vegfr current model
phase current evalu combin lucitanib rucaparib ovarian cancer
plan phase combin lucitanib opdivo gynecolog cancer expect
potenti posit catalyst fall like esmo updat data phase
rucaparib prostat cancer snda file rucaparib mcrpc base phase
initi phase athena trial data rucaparib combo opdivo
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt ovarian
breast cancer prostat cancer cash/pipelin rubraca look well posit
downsid risk relat failur compet failur expand cancer
page
page
top-line ariel data ovarian cancer brca mutat parprucaparib phase athena trial data first line ovarian cancer mainten set highparp oct esmo updat data phase mcrpc hrd expect initi respons orr initi phase ari relaps brca wild-typ ovarian cancer local advanc metastat bladder carcinoma parprucaparib data metastat castrat resist prostat cancer expect improv respons rucaparib monotherapi orrlowparp squibb bm rucaparib data gynecolog cancer expect manag safeti data prostat cancer germlin somat brca/atm mutat mcrpc ar therapi relaps chemo base acceler approv brcamut mcrpc expect accept snda announc phase gynecolog cancer lucitanib phase ovarian biotechnolog
page
expect firdaps revenu substanti better
summari compani launch firdaps treatment lem januari strong
initi patient adopt minim payer pushback think continu success firdaps launch
highli like ruzurgi market earli evalu potenti threat
firdaps also think data catalyst musk-mg provid addit upsid
report date earn call expect third week august
substanti stronger firdaps sale
may adult lem patient firdaps treatment posit insur
coverag uninsur patient insur patient without coverag catalyst provid free
bridg medic patient firdaps without delay march patient
receiv coverag reimburs averag monthli out-of-pocket amount
patient pay per month moreov time fill time reimburs
metric current trend better origin assumpt day recent
convers manag increment posit view firdaps
revenu substanti better beat top-line
ruzurgi market impact firdaps difficult determin
follow fda approv ruzurgi may jacobu launch ruzurgi websit promot
drug jacobu also provid patient assist program help patient determin whether
insur cover prescript one adult patient alreadi receiv shipment
suppli ruzurgi via pantherx specialti pharmaci post juli appear patient
firdaps switch back ruzurgi previous individu like
first patient receiv ruzurgi shipment given still earli stage ruzurgi launch difficult
determin impact firdaps catalyst manag heard lem patient
page
metric mn except epsstrh revenu substanti better sourc compani report factset strh researchfirdaps earli launch catalyst patient prescrib treat treat posit insur physician write one prior access strh research compani report biotechnolog
troubl get cover off-label use ruzurgi especi medicar current medicar cover
approxim lem patient commerci plan cover medicaid/va/dod
well government program cover remain without insur
coverag issu catalyst provid firdaps remain patient free charg
phase musk-mg data
catalyst expect report top-lin result phase trial musk-mg think top-lin
result posit given larg sampl size robust phase result report march
subsequ publish nonanno et al open medicin note
phase studi termin earli half enrol clinic benefit firdaps
particularli like open-label run-in dose-find phase employ phase
trial phase studi design patient must improv mgc
elig random help enrich respond patient phase three patient
random condit worsen patient could titrat effect dose
run-in phase three patient treat medic made either
inelig continu hospit
minimum ten gmg patient enrol phase musk-mg trial gmg patient
includ primari outcom analysi specif gmg patient screen
enrol minimum ten requir less ten gmg patient qualifi enrol
screen total enrol compani stop number gmg patient
reach catalyst stop gmg patient screen regardless number
enrol although clinicaltri gov list studi site compani inform us
patient enrol ex-u site well
manag state success phase studi musk-mg togeth complet
phase studi suffici regulatori file compani estim
musk-mg patient popul size least larg larger lem
expect call focu firdaps launch metric expect phase studi
musk-mg
valuat price target calcul take averag three valuat methodolog
discount earn model discount cash flow model clinic net present valu model
discount earn model appli multipl discount back discount cash
flow model employ industri standard discount rate perpetu growth rate
clinic npv model employ probabl success lem program
probabl success program probabl success musk-mg program
page
productstrh commentarytimingimpacttop-lin result phase trial musk-mgbas posit phase data expect phase trial meet primari result phase studyour kol consult highli posit firdaps efficaci result sma type proof-of-concept trialdata includ patient catalystseventsourc strh research compani report firdaps biotechnolog
risk risk rate price target includ regulatori risk commerci risk legal risk clinic
pipelin risk given ruzurgi approv lem pediatr patient commerci risk
ignor catalyst file law suit fda thu also legal risk pipelin risk
materi firdaps product candid clinic develop
page
page
sale revenu collabor revenue- net firdaps sale expensescogs- research gener sales- total oper interest expense- chang fair valu warrant pre-tax incom ep basic dilut averag share outstand basic sourc suntrust robinson humphey estim compani report biotechnolog
exelixi expect cabozantinib revenu line-to-abov consensu focu
competit dynam expand market potenti cabozantinib
summari expect cabozantinib revenu line-to-abov consensu mn
growth driven open indic kidney io move
opportun renal expand use liver expect earn focu
cabozantinib market dynam renal liverw look impact current market share
post-io set renal continu uptak liver cancer expans cabozantinib
franchis multipl combin io kidney liver broader object
continu growth plan expand pipelin beyond cabozantinib
compani report factset strh research estim juli
report date earn call wednesday juli et us dial-in code
expect cabozantinib revenu line-to-abov street consensu base analysi
monthli im script price data exhibit expect revenu cabozantinib
line-to-abov street mn furthermor manag strong record beat top
bottom line see exhibit consensu impli q/q last quarter follow miss
due headwind report last quarter believ growth momentum pick back
exhibit adjust script volum analysi point mn analysisin line-to-abov
strh research data juli
red miss earn non-gaap revenu sale plu royalti exclud mileston green beat grey in-line price
reaction reflect stock reaction day prior earn compar day earn
consensu cabozantinib mn adjust follow miss steadi go
quarter estim quarter cabozantinib consensu adjust
mn mn follow miss due headwind see note
hold stead quarter
page
metric mn except epsstrh metric cabozantinib cabometyx expect cabo sale line-to-abov non-eventrevenu actual consensu script analysi cabometyx growth strh script reaction biotechnolog
focu demand growth rcc cabo take patient post-io help growth
io/io io/tki becom avail liver cancer market build help
expect discuss market dynam renal cell carcinoma rcc hepatocellular carcinoma
remind cabo hold tki market renal patient progress
io combin see healthcar theme piec focus post-io set
io combin move see
opportun demand growth cabo recal combin ipilimumab plu
nivolumab approv last april combo pembrolizumab plu axitinib tki
approv april recal cabo approv jan believ
hepatologist refer patient oncologist oppos intervent radiologist see
demand cabo liver cancer would watch see approv regorafenib
help shape treatment landscap
focu expans reiter expans opportun expect manag
reiter focu longer term expans opportun believ variou on-going clinic trial
provid multipl shot expand cabo franchis thyroid enrol open
oct phase evalu cabo radioiodine-refractori differenti thyroid
cancer co-primari endpoint os orr analysi among first patient
potenti file pend data combo liver phase initi dec
evalu combin cabo atezolizumab advanc liver cancer hepatocellular
carcinoma co-primari endpoint independ radiolog committe os
orr secondari endpoint combo variou tumor phase
continu progress
new cohort ad month see note
evalu combin cabo atezolizumab data readout yet
updat manag guid wait matur suffici time data
meaning checkmat combo kidney phase checkmat conduct partner
bristol-my squibb nr result expect earli remind believ
competitor merck nr set bar beat howev base
upon initi result believ data beatabl see note lastli
new pipelin candid inhibitor vegf first restart discoveri
program subject activ ind file oct
potenti posit catalyst phase data cabometyx tecentriq
multipl tumor phase data cabo io non-smal cell lung cancer tripl
neg breast cancer endometri cancer earli checkmat opdivo
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt renal cancer
liver cancer cash/pipelin bull/bear case model yield pt
cabozantinib look well posit downsid risk relat failur commerci competit
failur expand cancer
cohort
page
page
assettimingcatalystcommentaryimpacttargettrialcollaborationpartnershipcabozantinib data dose find multipl tumor expect orr standard caremediummet genentechipsen takedacabozantinib opdivoearli primari data line rcc expec match beat surviv benefit squibbipsen takedacabozantinib opdivo earli safety/efficaci data line hepatocellular carcinoma expect orr squibbipsen takedacabozantinib data non-smal cell lung cancer tripl neg breast cancer endometri cancer expect orr standard caremediummet takeda biotechnolog
page
incyt corpor expect jakafi sale line consensu
summari expect jakafi sale line consensu expect focu earn
call jakafi revenuesw expect line consensu consensu mn expect fy
guidanc reiter wont surpris see modest upsid reiter data
timelin start yearfocu diversifi futur revenu beyond mf/pv includ earli post-
approv activ jakafi gvhd
compani report factset strh research estim juli
report date earn call tuesday juli et us dial-in code press releas
et
expect jakafi revenu line consensu expect jakafi revenu line
consensu project mn vs consensu mn repres q/q growth
remind manag reiter guidanc exhibit
consensu jakafi mn steadi sinc estim quarter jakafi
spread rang mn mn around mean mn mean estim
page
metric mn except epsstrh metric jakafi jakafi expect sale line non-eventdateqd mnyear-end actual mn ye net product revenu guidanc biotechnolog
held steadi head quarter remind jakafi product sale miss consensu last quarter
mn vs consensu mn exhibit believ concern miss due donut hole
higher gross-to-net see note
red miss earn jakafi product revenu green beat grey in-lin guidanc arrow reflect initi annual guidanc
street subsequ guid raised/low guidanc price reaction reflect stock reaction day prior
earn compar day earn
dont expect chang upcom timelin focu diversifi futur revenu beyond jakafi
mf/pv includ earli post-approv activ jakafi gvhd dont expect chang catalyst
data phase trial ruxolitinib steroid-refractori acut graft-versus-host diseas sr-agvhd
phase data sr-cgvhd data phase evalu
itacitinib steroid-nav agvhd addit expect file nda pemigatinib
cholangiocarcinoma also intrigu develop oral small molecul pd-
inhibitor could highli differenti final partner eli lilli nr also expect
present data phase baricitinib atop dermat expect minor comment
around post-commerci activ jakafi launch steroid-refractori acut graft-versus-host diseas approv
potenti posit catalyst top line data phase evalu ruxolitinib steroid-
refractori agvhd trial top line data phase evalu ruxolitinib steroid-refractori
cgvhd trial pivot data phase evalu itacitinib treatment-nav agvhd
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt jakafi mf pv
gvhd olumi iclusig cash/ pipelin bull/bear case model yield
pt risk includ failur clinic develop competit impact jakafi olumi uptak
page
page
data solid data solid tumor gitrbaricitinib phase atop data nsclc glioblastoma liver cancer c-metnovartisruxolitnib week phase data phase registr studi registr data data steroid-refractori agvhd expect orr data steroid-refractori cgvhd expect orr data advanc malign includ pimjakafi data file fgfr transloc file bladder data newly-diagnos acut gvhd expect orr initi treatment-nav chronic gvhd phase target clinic candid annouc biotechnolog
page
quarterli sale royaltiesjakafi jakafi gvhd/transplant- iclusig cml- product total fair valu acquisit incom incom non-gaap inc net incom non-gaap ex incom ep product share outstand biotechnolog
expect giapreza revenu slightli consensu
summari compani launch giapreza vasoconstrictor indic increas blood pressur
adult septic distribut shock march seen full report year
sale drug sequenti quarterli growth averag think continu success
giapreza highli like track meet manag full year guidanc
addit think full data phase hh studi expect could provid
giapreza still earli stage commerci nomin sale contribut
expect giapreza revenu slightli consensu vs repres q/q
growth peak model giapreza market share catecholamin resist hypertens crh
market reach also look updat ec approv follow ema chmp posit
opinion grant june eu sale commenc model separ think
updat surviv sepsi guidelin may come earli could includ giapreza
algorithm would signific tailwind beyond loss per share
assum expens sg expens base share count
report date yet announc potenti first week august
continu focu like full phase data hh
hereditari
hemochromatosi hh compani hit pre-specified endpoint tsat statist
signific achiev impress given subject less half
patient expect enrol includ interim analysi yet includ hh
valuat think market opportun hh signific current standard care larg
inadequ note
page
see slightli higher sale giapreza vs larg line price
eu giapreza launch would expect eu region licens deal prior launch
phase full data hercul studi hh expect sustain serum iron
reduct program advanc phase base posit preliminari data
pivot phase ii top-line data helio studi -thal see low bar given
unmet need nda submiss malaria appear schedul
valuat risk
pt base net-present-valu npv sum-of-the-part sotp analysi includ
giapreza sale probability-adjust npv beta-thalassemia
compani current net cash posit use discount rate giapreza
respect termin growth rate believ appropri similar stage compani
risk includ clinic setback competit
page
page
productstrh commentarytimingimpact giapreza angiotensin ii eu giapreza launchw anticip eu region licens deal prior eu ii hercul hereditari hemochromatosi full databas highli posit interim data expect sustain serum iron reduct program advanc phase phase ii studi -thal helio top-line datagiven unmet need believ bar success beta-th submiss malariarec receiv btd fda nda schedul biotechnolog
page
revenuegiapreza sales- giapreza ou royalties- sales- total product collabor total cog giapreza- royalti hcr- cog total cog inlclud royalti hcr gross total oper oper incom incom incom incom incom tax gain ep dilut share outstand rsu outstand equival begin secondari offer dilut third parti fund non-dilut net capit raise- impli equival end equival per mm biotechnolog
gene therapi readout
summari revenu estim slightli street major catalyst includ
data third dose cohort phase i/ii studi well data second dose
cohort expect mid-year think second dose could optim dose
reiter buy pt
report date earn call august dial passcod
crysvita mepsevii launch progress
crysvita revenu in-lin street estim earli launch metric
crysvita show sign slight slowdown growth evidenc reduc number
ad patient start form quarter ultragenyx focus maxim valu
exist crysvita prescrib expand prescrib base creat referr pathway reduc time
reimburs day day identifi addit xlh patient
mepsevii revenu growth plat
sale mepsevii miss consensu expect revenu growth mepsevii flat
quarter quarter signal potenti challeng identifi addit mp vii patient
page
metric mn except epsstrh sourc compani report factset strh researchexhibit crysvita launch metricscrysvitapati start formsuniqu prescriberspati reimburs therapynave-to-treat ped adult ratiopriv public payer ratiocov compani report strh research biotechnolog
nda submiss
encourag fda willing review nda base exist data
nda accept submiss compani expect receiv prioriti review design
commun fda within day receipt nda ultragenyx note addit
sale forc need market drug approv sinc exist sale forc alreadi
target endocrinologist treat lc-faod believ data packag compel efficaci
signal observ unlik due diet chang
gene therapi readout
high convict phase studi gsdia base impress first cohort data
second cohort three patient receiv singl dose vg/kg abil
extend time hypoglycemia allow safe sleep night hour would key metric
watch phase enabl
second program phase over-the-counter defici septemb ultragenyx report
mix data cohort phase i/ii studi over-the-counter defici one three
patient respond respons seem durabl least one year base data
cohort compani plan increas dose order magnitud vg/kg cohort
vs vg/kg use cohort base manag comment would consid two three
patient normal ureagenesi win cohort optimist base increas
compani decid build in-hous manufactur plant supplement contract
manufactur organ meantim compani abl run full scale manufactur
oper process develop transfer process outsid contract manufactur
exist gene therapi program regard manufactur platform ultragenyx reli
suspens platform hela suspens platform
rich preclin asset leverag four therapeut modal tradit biolog
choos suitabl modal right diseas make lot sens us
strength weak modal think basket tool hand ultragenyx
provid greater flexibl target greater number diseas seen clinic success
page
exhibit sale crystiva mepsevii timesourc compani report strh research revenu mm mepsevii salestot crysvita revenu book ultragenyx biotechnolog
use tradit biolog crysvita mepsevii earli clinic proof-of-concept data aav
gene therapi
valuat arriv price target take averag three differ
valuat methodolog discount earn model discount cash flow model clinic net
present valu model discount earn model appli multipl discount back
discount cash flow model employ industri standard discount rate
perpetu growth rate clinic npv model employ probabl success
probabl success probabl success also
ad technolog platform valu model encompass gene therapi mrna
risk rate price target includ
clinic develop risk uncertainli whether earlier stage experi
preclin phase histor case report translat efficaci phase
regulatori risk even upon success clinic data fda may view result worthi
regulatori approv commerci sale particular highlight risk fda
accept certain biomark endpoint acceler approv pathway
commerci risk product may fail achiev revenu line peak estim
commerci market
competit risk emerg compet therapi may reduc ultragenyx market
partnership risk ultragenyx reli partnership therapi
particular khk manufactur commerci product thu ultragenyx
vulner shortcom partner
manag risk ultragenyx assembl team all-star rare diseas world
especi ceo emil kakki certain employe leav inopportun time may
damag compani chanc success
financ risk develop stage compani ultragenyx profit may turn
profit near futur futur financ may requir develop drug may
page
productstrh commentarytimingimpact submit nda fda lc-faodth compani reach agreement fda detail nda updat data third cohort phase i/ii studi over-the-counter deficiencyth lack dose respons data phase i/ii cohort gsdiadata first cohort crysvita regulatori decis brazil colombiaw expect mepsevii regulatori decis columbia chilew expect catalystseventsourc strh research compani report biotechnolog
page
joon md pharmaceuticalrequir disclosur last tab workbook consolid incom statement mm except per share collabor licens includ revenu bayer crysvita-u revenu research agreement total crysvita revenu book ultragenyx- crysvita burosumab /canada profit share/royalty- crysvita burosumab royalty- crysvita burosumab revenu book ultragenyx latin america- mepsevii triheptanoin revenu revenue- revenue- total cog cog net product sale exclud gross expens sg sg oper expens oper incom total expens incom net gain loss tax tax net incom loss attribut common ep basic ep dilut weight share sourc suntrust robinson humphrey compani sec file
